Across TCGA pan-cancer cohorts, EI24 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated EI24 data layer compared with 29 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in breast invasive carcinoma (BRCA), where higher EI24 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated EI24 expression acts as an unfavorable survival marker.
BRCA, LIHC, and SARC are the cancer types where EI24 Mutation most reproducibly stratifies survival.